Table 3.
Adjusted incidence rate ratios for all-cause and cardiovascular mortality for patients with serum phosphate levels stratified by serum intact parathyroid hormone levels
| Outcomes | Serum phosphate (mg/dL) | aIRR (95% CI) | Interaction | |
|---|---|---|---|---|
| iPTH < 300 pg/mL | iPTH ≥ 300 pg/mL | |||
| All-cause mortality | < 4.0 | 1.25 (0.94–1.66) | 1.36 (0.76–2.42) | P = 0.207 |
| P = 0.129 | P = 0.298 | |||
| ≥ 4.0–< 7.0 | Ref | Ref | ||
| ≥ 7.0 | 1.58 (1.06–2.36) | 3.23 (1.63–6.39) | ||
| P = 0.026 | P < 0.001 | |||
| Cardiovascular mortality | < 4.0 | 0.81 (0.53–1.24) | 0.90 (0.37–2.17) | P = 0.366 |
| P = 0.329 | P = 0.815 | |||
| ≥ 4.0–< 7.0 | Ref | Ref | ||
| ≥ 7.0 | 1.41 (0.84–2.36) | 2.41 (1.11–5.21) | ||
| P = 0.192 | P = 0.025 | |||
aIRR adjusted incidence rate ratio, CI confidence interval, iPTH intact parathyroid hormone, ref reference
Incidence rate ratios were adjusted for patients’ characteristics (age, sex, primary kidney disease, diabetes, dialysis duration, cardiovascular disease, pulmonary disease, liver disease, malignancy, and history of parathyroidectomy) and time-dependent variables (vitamin D receptor activators, phosphate binders, calcimimetics, serum albumin level, hemoglobin level, body mass index, Kt/V, and dialysate calcium concentration)